Arthritis Advisory Committee; Notice of Postponement of Meeting, 8266 [E9-3830]
Download as PDF
<![CDATA[
8266
Federal Register / Vol. 74, No. 35 / Tuesday, February 24, 2009 / Notices
development for HAP and VAP. This
public workshop will focus on scientific
considerations in designing clinical
trials for HAP and VAP. Topics for
discussion include the following: (1)
Approaches to the diagnosis of HAP and
VAP, (2) the effect of antimicrobial
treatment for HAP and VAP, (3) various
endpoints that might be considered as
endpoints for trials of HAP and VAP,
and (4) statistical issues in analysis of
results from trials in HAP and VAP. The
input from this public workshop will
help in developing topics for further
discussion.
The agency encourages individuals,
patient advocates, industry, consumer
groups, health care professionals,
researchers, and other interested
persons to attend this public workshop.
Transcripts: Transcripts of the public
workshop may be requested in writing
from the Freedom of Information Office
(HFI–35), Food and Drug
Administration, 5600 Fishers Lane, rm.
6–30, Rockville, MD 20857,
approximately 20 working days after the
public workshop at a cost of 10 cents
per page. Transcripts will also be
available on the Internet at https://
www.fda.gov/cder/meeting/
hap_vap.htm approximately 45 days
after the workshop.
Dated: February 17, 2009.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E9–3832 Filed 2–23–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0664]
Arthritis Advisory Committee; Notice
of Postponement of Meeting
AGENCY:
Food and Drug Administration,
HHS.
mstockstill on PROD1PC66 with NOTICES
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is postponing the
meeting of the Arthritis Advisory
Committee scheduled for March 5, 2009.
This meeting was announced in the
Federal Register of January 29, 2009 (74
FR 5165). The postponement is due to
the need to complete the review of
additional data submitted by the
applicant. Future meeting dates will be
announced in the Federal Register.
FOR FURTHER INFORMATION CONTACT:
Nicole Vesely, Center for Drug
Evaluation and Research (HFD–21),
VerDate Nov<24>2008
17:23 Feb 23, 2009
Jkt 217001
Food and Drug Administration, 5600
Fishers Lane (for express delivery, 5630
Fishers Lane, rm. 1093), Rockville, MD
20857, 301–827–6793, FAX: 301–827–
6776, e-mail: nicole.vesely@fda.hhs.gov,
or FDA Advisory Committee
Information Line, 1–800–741–8138
(301–443–0572 in the Washington, DC
area), code 3014512532. Please call the
Information Line for up-to-date
information on this meeting.
Dated: February 18, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–3952 Filed 2–23–09; 8:45 am]
Dated: February 17, 2009.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E9–3830 Filed 2–23–09; 8:45 am]
National Institutes of Health
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development Initial
Review Group; Obstetrics and Maternal-Fetal
Biology Subcommittee.
Date: March 23, 2009.
Time: 9 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: Courtyard Gaithersburg
Washingtonian Center, 204 Boardwalk Place,
Gaithersburg, MD 20878.
Contact Person: Gopal M. Bhatnagar, PhD,
Scientific Review Administrator, National
Institute of Child Health and Human
Development, National Institutes of Health,
6100 Executive Blvd., Rm. 5b01, Rockville,
MD 20852, (301) 435–6889,
bhatnagg@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development Initial
Review Group. Population Sciences
Subcommittee.
Date: March 26–27, 2009.
Time: 8 a.m to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Madison Hotel, 1177 15th
Street, NW., Washington, DC 20005.
Contact Person: Carla T. Walls, PhD,
Scientific Review Administratior, Division of
Scientific Review, National Institute of Child
Health, and Human Development, NIH, 6100
Executive Blvd., Room 5B01, Bethesda, MD
20892, (301) 435–6898, wallsc@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: February 18, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–3956 Filed 2–23–09; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\24FEN1.SGM
24FEN1
]]>Agencies
[Federal Register Volume 74, Number 35 (Tuesday, February 24, 2009)]
[Notices]
[Page 8266]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-3830]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2009-N-0664]
Arthritis Advisory Committee; Notice of Postponement of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is postponing the
meeting of the Arthritis Advisory Committee scheduled for March 5,
2009. This meeting was announced in the Federal Register of January 29,
2009 (74 FR 5165). The postponement is due to the need to complete the
review of additional data submitted by the applicant. Future meeting
dates will be announced in the Federal Register.
FOR FURTHER INFORMATION CONTACT: Nicole Vesely, Center for Drug
Evaluation and Research (HFD-21), Food and Drug Administration, 5600
Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093),
Rockville, MD 20857, 301-827-6793, FAX: 301-827-6776, e-mail:
nicole.vesely@fda.hhs.gov, or FDA Advisory Committee Information Line,
1-800-741-8138 (301-443-0572 in the Washington, DC area), code
3014512532. Please call the Information Line for up-to-date information
on this meeting.
Dated: February 17, 2009.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E9-3830 Filed 2-23-09; 8:45 am]
BILLING CODE 4160-01-S
